HOME › Research Insight › New Product Launches and Mergers, Agreements, and Collaborations Are the Key Growth Strategies in the Nucleic Acid Isolation and Purification Market
New Product Launches and Mergers, Agreements, and Collaborations Are the Key Growth Strategies in the Nucleic Acid Isolation and Purification Market
The major players in the nucleic acid isolation and purification market include Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher Corporation (U.S.), Illumina Inc. (U.S.), Life Technologies (U.S.), Promega Corporation (U.S.), Qiagen (Netherlands), Roche Applied Sciences (Germany), and Thermo Fischer Scientific Inc. (U.S.).
Nucleic acid isolation in the pure form is an important step for various downstream molecular biology applications. In the past, methods used to extract nucleic acids were time-consuming, labor-intensive, complex, and limited in terms of throughput. Presently, many specialized methods are available, from conventional solution-based approaches to solid-phase systems, which are commercialized as kits and instruments.
The global nucleic acid isolation and purification industry is in the nascent stage, presenting significant growth potential. Most players in this market are aiming to either diversify their product portfolios or expand their geographic presence to maintain their market shares. During 2011 to 2014, new product launches and collaborative partnerships were the key strategies followed by major players. The collaborative partnerships strategy was employed by players to gain immediate technological competency and widen their geographic presence. For instance in July 2013, QIAGEN partnered with Exosome Diagnostics Inc. (U.S.) to develop and commercialize high-performance sample preparation kits for the processing of nucleic acids from exosomes. The key players who adopted collaborative partnerships as a growth strategy included Illumina Inc. (U.S.), GE Healthcare (U.K.), Life Technologies (U.S.), Qiagen (Netherlands), and Roche Applied Sciences (Germany).
The second most key strategy adopted by major players was new product launches. The new launches primarily included kits used for nucleic acid isolation and purification. Most of the newly launched kits were based on silica column- and magnetic bead-based technologies. This strategy was mainly adopted by Illumina Inc. (U.S.), GE Healthcare (U.K.), Life Technologies (U.S.), Qiagen (Netherlands), and Roche Applied Sciences (Germany). Companies adopted these strategies in order to expand their product portfolios and to strengthen their market presence.
Nucleic Acid Isolation and Purification Market by Technology (Column based, Reagent based, Magnetic bead based), Consumables & Instruments, Application (Plasmid DNA isolation, MIRNA isolation, Total RNA isolation) & by End Users - Global Forecasts to 2018
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252